Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 4 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Board fully replaced NBB
No director from three years ago is still active according to annual account 2025.
-
Not on Peppol Peppol
Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.
Financials
Financial year 2025
Enzo Life Sciences from Elsene, company number BE0459284211, closed financial year 2025 with a result of € -185,783 after tax. For that financial year Enzo Life Sciences recorded revenue of € 814,945 and equity of € -1 million. Compared with financial year 2024, the result moved from € -136,245 to € -185,783. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on January 14, 2026.
€ -1 million
▼ € 185,783 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -185,783
▼ 36 % more loss than in 2024
Profit after tax over the fiscal year.
€ 30,055
▼ 39% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -1 million.
People and assets in 2025
1
Average over the fiscal year, from the social balance sheet.
€ 131,031
€ 131,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 73,580
▲ 136% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 31 days on average.
€ 26,297
▼ 22% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 1,083,209 | € 1,329,915 | € 2,180,284 | € 814,945 | ▼ 63% |
| Profit after taxes | € -77,955 | € -143,661 | € -136,245 | € -185,783 | ▼ € 49,538 |
| Equity | € -565,467 | € -709,128 | € -845,373 | € -1,031,156 | ▼ € 185,783 |
| Total debts | € 842,739 | € 980,120 | € 1,348,879 | € 1,173,849 | ▼ 13% |
| Cash | € 21,751 | € 30,217 | € 49,440 | € 30,055 | ▼ 39% |
| Retained profit | € -584,059 | € -727,720 | € -863,965 | € -1,049,748 | ▼ € 185,783 |
| Balance sheet total | € 277,272 | € 270,992 | € 503,506 | € 142,693 | ▼ 72% |
| Employees (FTE) | 1 | 1 | 1 | 1 |
By revenue, Enzo Life Sciences ranks 9th of 9 companies with main activity “Groothandel in farmaceutische en medische artikelen” in Elsene that publish figures (fiscal year 2025).
Key figures of Enzo Life Sciences, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 3 March 2027.
Ask about Enzo Life Sciences the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to Enzo Life Sciences?
What happened at Enzo Life Sciences in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 185,783. Source: NBB ↗
- Jason Apter became a director. NBB
- Kara Anne Cannon stepped down as director. NBB
- Kara Anne Cannon became a director. NBB
- New establishment in Elsene. KBO
- Start of the company according to the CBE. KBO
In short
From € 77,955 loss in 2022 to € 185,783 loss in 2025.
Pays suppliers within 31 days on average.
Management
Behind Enzo Life Sciences is Jason Apter.
Directors
According to the 2025 annual accounts
Jason Apter
Director
since 2025
Kara Anne Cannon
Director
since 2023 · until 2025
Establishments
Establishment units
Physical locations of this company
Louizalaan 65 box 11
1050 Elsene
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Similar companies in Elsene
Same main activity (Groothandel in farmaceutische en medische artikelen), 32 active companies in Elsene, largest first.
€ 164.7 million revenue · 2025
€ 96.9 million revenue · 2025
Boehringer Ingelheim Animal Health Belgium SA
€ 50.6 million revenue · 2025
€ 23.5 million revenue · 2025
€ 21.4 million revenue · 2026
€ 16.2 million revenue · 2025
Details
- Company number
- 0459.284.211
- VAT number
- BE 0459.284.211
- Registered office
- Louizalaan 65 bus 11, 1050 Elsene
- Names & denominations
- Enzo Life Sciences
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 25 November 1996
- Peppol
- Not registered
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Overige groothandel
Reparatie en onderhoud van consumentenartikelen, neg
Niet-gespecialiseerde groothandel
Overige detailhandel in nieuwe artikelen neg
Handelsbemiddeling in de niet-gespecialiseerde groothandel
Handelsbemiddeling in goederen, algemeen assortiment
Overige gespecialiseerde detailhandel in artikelen, andere dan voedingsmiddelen, n.e.g.
+1